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Background: Medication-related osteonecrosis of the jaws (MRONJ) is a prominent complication and
growing problem related to the oral and maxillofacial region due to antiresorptive and antiangiogenic
agents. Awareness about MRONJ is crucial for all dental practitioners identify ‘at risk’ patients for
appropriate advice and management. This cross-sectional survey aimed to appraise MRONJ awareness
and knowledge among dentists.
Materials and methods: A questionnaire-based survey was carried out through one hundred and seventy
eight dentist who recruited in three groups; the first group comprised 113 general dental practitioners
(GDP), 33 dental radiologist (DR) included in the second, and 32 oral and maxillofacial surgeon (OMS) in
the third group. MRONJ awareness was evaluated by asking all respondents a question of “Did you heard
about MRONJ? In addition, the detailed knowledge on the subject in question were addressed through
fourteen, nine, and three questions for OMSs, DRs, and GDPs respectively.
Results: A significant difference were existed among groups with a rate of MRONJ's awareness of 33.6%,
48.5%, and 84.4% for GDPs, DRs, and OMSs respectively. Concerning MRONJ knowledge, significantly
highest rates seen in OMSs set with 48.55%. In contrast, the average scores of DRs were 30.64%, and the
GDPs group recorded the least value with 16.67%.
Conclusions: Strengthen the MRONJ awareness and knowledge among general dentists and dental
specialists are essential to identify ‘at risk’ patients for appropriate advice and management.
© 2019 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Bisphosphonate (BP) as antiresorptive agent were used for
prevention of bone loss since the late 1960s (Fleisch, 2002), but in
2003, the first case of bisphosphonate-related osteonecrosis of the
jaws (BRONJ) was reported (Marx, 2003). Then many cases have
reported by different researchers (Leite et al., 2006; Melo and
Obeid, 2005; Ruggiero et al., 2004; Greenberg, 2004) especially
when bisphosphonates infused intravenously for patients with
cancer andmetastatic bone disease (Wooltorton, 2005).In 2005, the
manufacturer of BP considered the risk of BRONJ on their labelling
including all the intravenous and oral preparations (Tanna et al.,
2017).. Al-Samman), rand_shaker@
axillo-Facial Surgery. Published byDenosumab; another antiresorptive agent; and the anti-
angiogenic agents like sunitinib and bevacizumab were also found
to cause jaw necrosis (Papapoulos et al., 2012; Christodoulou et al.,
2009), hence the nomenclature of BRONJ changed by the American
Association of Oral and Maxillofacial Surgeons to medication-
related osteonecrosis of the jaws (MRONJ) (Ruggiero et al., 2014).
MRONJ is a growing problem since the number of patients
receiving bisphosphonates is increasing. For example, in U.K., the
incidence of MRONJ were 0.001% as estimated in 2012, with
increasing number of dispensed prescriptions by 2.5% over 7 years
(Faculty of General Dental Practice, 2012). While the American
Association of Oral and Maxillofacial Surgeons reported higher
incidence of 0.004% and 0.1% in 2014 (Ruggiero et al., 2014).
MRONJ can remain asymptomatic for long periods in the
absence of infection; however, certain radiographic findings could
improve its early detection (Treister et al., 2009; Hutchinson et al.,
2010). That is why awareness about MRONJ is crucial for dental
radiologists for their role in diagnosis of oro-facial problems.Elsevier Ltd. All rights reserved.
Fig. 1. Questionnaire used for data collection from oral and maxillofacial surgeons.
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because they perform the primary dental care and for dental sur-
geons as they are concerned with treatment of many of dento-
alveolar problems that require surgical intervention.
This cross-sectional study aims to appraise MRONJ awareness
and knowledge among dentists.
2. Material and methods
A cross-sectional based survey was carried out amongst a
sample of dentists working in five Iraqi cites. Respondents were
recruited in three groups; oral and maxillofacial surgeons (OMS),
dental radiologist (DR), and general dental practitioners (GDP).
Over a period of six weeks, three trained specialist dentists
administered the questionnaires to 178 dentist (113 GDP, 32 OMS,
and 33 DR) who informed about the study protocol and the
participation was voluntary and anonymous.
The questionnaire was designed for two objectives: to get an
overview of the OMSs, DRs, and GDPs’ knowledge of MRONJ, and to
evaluate the differences among grades.
Demographic data, years of experience, the university that
awarded the certificate and affiliationwere included in the first part
of the questionnaire in addition to two questions “Did you heard
aboutMRONJ?, “Within the last three years, did you read a scientific
paper or attends a scientific lecture about MRONJ?”
Only respondents who answered “yes” for the first question
passed to the second part of the questionnaire and excluding others
with answer “no” thereby removing false positive answers. The
second part addressed the detailed knowledge about MRONJ. This
was analyzed through fourteen, nine, and three questions for OMSs,
DRs, and GDPs respectively (Figs. 1e3).
The questions of 14-item questionnaire were distributed based
on 6 groups: the first group comprised 2 questions and investigated
medical condition that may treated with osteonecrotic drugs and to
name these drugs. The second group question evaluated the sur-
geons' willingness of tooth extraction in patients receiving osteo-
necrotic drugs. The third group questions were 3 and related to
MRONJ diagnosis. In the fourth group, three questions focused on
seriousness of BP, and how it works. Information about how sur-
geons deal with MRONJ patients are available through 4 questions.
The last group question assess surgeons'’ knowledge about the
advance MRONJ treatment modalities.
A 9-question self-administered questionnaire was sectioned
into three groups. The first group comprised 2 questions and
evaluated the ability of DRs in formulating differential diagnosis.
Six questions included in the second group and clarified how DRs
correlate between the patients’ medical history and the site of the
lesion to reach diagnosis. The last group question assessed their
ability to use appropriate imaging technique as indicated.
The GDPs questionnaire comprised the same first 3 questions of
OMSs questionnaire.
‘Right’, incomplete right, or ‘wrong’ answers were assigned by 1,
0.5, or 0 points. The higher score represented better knowledge.
The questionnaire were completed and returned immediately.
The data analyzed using IBM SPSS Statistics for Windows
(version 23, IBM Corp. Armonk, NY, USA). The significance of dif-
ferences within groups and between the groups were assessed
using and the independent sample T-test, analysis of variance (one-
way ANOVA), and Duncan test considering a probability values less
than 0.05 as significant.
3. Results
Two hundred and five dentist were asked to participate in the
survey. Twenty-seven (13.2%) exhibit no interest to participate. One
Fig. 2. Questionnaire used for data collection from dental radiologists.
Fig. 3. Questionnaire used for data collection from general dental practitioners.
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DRs, and 113 GDPs). They were 93 males (52.2%) and 85 were fe-
males (47.8%). Their mean age and experience were 33.55
(SD ± 8.75) and 7.79 (SD ± 7.32) respectively. Fifty-two participants
(29.2%) worked in primary dental care clinics. Others worked inspecialized (secondary) dental centers (63, 35.4%), hospitals (16,
9%) and universities (47, 26.4 %).
The vast majority of participants (97.2%) were graduated from
Iraqi universities (8 governmental and 3 private universities),
whereas the rest of participants were qualified from 1 Asian and 2
European universities (Table 1).
The OMSs group, their mean experience were 9.16 years
(SD ± 5.71). Five surgeons (15.6%) not aware of MRONJ and 18/27
(66.7%) surgeons, those had previous MRONJ knowledge, read a
scientific topic concerning MRONJ within the last 3 years (Table 2).
Concerning first group questions, 25% of surgeons reported
correct answer for question number 1, in contrast, only one surgeon
mentioned denosumab as a possible osteonecrotic drug and none
of them was mentioned any antiangiogenic agent.
Forty percent were satisfied with tooth extraction for BP pa-
tients, but more than half of them reported wrong regimen in
dealing with such patients. For surgeons who do not like to extract,
63.2% of them were wrong in how to deal with patients.
By surveying the surgeons' susceptibility to diagnose MRONJ, it
was evident that almost half of themwere correct in their diagnosis.
When asking about the seriousness of BPs and their mode of
action, 37% and 21.1% of respondents reported right and incomplete
right answers.
Questions on how surgeons treat MRONJ patients showed that
52.8% of them were correct, however, 60% of surgeons were un-
aware about advance treatment modalities.
Table 1
Demographic background of respondents.




Affiliation University of graduation
MHE MOH Govern-ment Private Foreign
GDPs 113 52 (46%) 61 (54%) 30.4 (7.779) 7.05 (7.68) 11 (9.7%) 102 (90.3%) 96 (85%) 16 (14.1%) 1 (0.9%)
DRs 33 15 (45.5%) 18 (54.5%) 38.78 (6.568) 9 (7.66) 19 (57.6%) 14 (42.4%) 33 (100%) 0 (0%) 0 (0%)
OMSs 32 26 (81.2%) 6 (18.8%) 41 (5.902) 9.16 (5.71) 17 (53.1%) 15 (46.9%) 28 (87.5%) 0 (0%) 4 (12.5%)
All respondents 178 93 (52.2%) 85 (47.8%) 33.55 (8.75) 7.79 (7.32) 47 (24.4%) 131 (75.6%) 157 (88.2%) 16 (9%) 5 (2.8%)
GDPs: General dental practitioners. DRs: Dental radiologists. OMSs: Oral and maxillofacial surgeons. MHE: Ministry of Higher Education, MOH: Ministry of Health.
Table 2
MRONJ's awareness, self-education and knowledge rate for all groups.
Q1: Have you heard about MRONJ? Q2: Have you read about MRONJ?a Average of MRONJ knowledge
Yes n,% No n.,% Yes n,% No n.,%
GDPs 38, (33.6%) 75, (66.4%) 5/38, (13.2%) 33/38 (86.8%) 16.67%
DRs 16 (48.5%) 17 (51.5%) 10/16 (62.5%) 6/16 (37.5%) 30.64%
OMSs 27, (84.4%) 5, (15.6%) 18/27 (66.7%) 9/27 (33.3%) 48.55%
All respondents 81 (45.5%) 97 (55.5%) 33/81 (40.7%) 48/81 (59.3%) 33.67%
MRONJ: Medication-Related Osteonecrosis of the Jaws. GDPs: General dental practitioners. DRs: Dental radiologists. OMSs: Oral and maxillofacial surgeons.
a Only respondents who answered “yes” for the first question were included.
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48.55%. In details, the surgeons working in the centers and hospi-
tals of the Ministry of Health (MOH) reported MRONJ's rate of
knowledge of 52.1%, and a higher proportion of them (94.1%)heard
about MRONJ before compared to 47.7%, 78.9% for surgeons affili-
ated to Ministry of Higher Education (MHE) but with no significant
differences (p ¼ 0.372, 0.188). In contrast, a significant more MOH
surgeons read a scientific topic related toMRONJ compared to other
surgeons (p ¼ 0.044) (Table 3).
By evaluating DRs group, the mean of their experience were 9
years (SD ± 7.66). Unfortunately, half of them (17, 51.5%) were not
aware of MRONJ and within the last three years, only 62.5% of the
rest of respondents in this group improved their knowledge by
reading a scientific paper(s) concerning MRONJ (Table 2).
DRs reported 21.9% correct answer for the first group questions
and about two thirds of them present with incomplete right an-
swers. Answers of the second group questions showed a higher
percent of correct answers with 35.6%. However, the incorrect an-
swers were also comparable in this group.
Highest percent of incorrect answers were recorded (87.5%)
when asking about the indication of panoramic radiography for
MRONJ patients.
Nineteen DRs (57.6%) affiliated to MHE with an average of
MRONJ knowledge of 36.8% compared to 21.8% for those working in
MOH centers and hospitals. However, comparable results were
existed between groups in respect to their awareness about, and
reading of scientific topic related to MRONJ (Table 3).
Regarding the GDPs set, their mean experience were 7.05 years
(SD ± 7.68). Seventy-five dentist (66.4%) never heard about MRONJ
before, and only 5 (13.2%) dentists from the rest of GDPs group readTable 3
MRONJ's awareness, self-education and knowledge rate among MOH and MHE specialist
OMSs-MOH OMSs-MHE
Heard about MRONJ before 94.1% 78.9%
Read about MRONJ 70.6% 42.1%
Average MRONJ knowledge 52.1% 47.7%
MRONJ: Medication-Related Osteonecrosis of the Jaws. OMSs: Oral andMaxillofacial Surg
Health.
*Significant (p < 0.05).a scientific topic and/or banning a scientific debate concerning
MRONJ within the last 3 years.
Answers of questions in the second part of questionnaire
revealed that only 1 dentist (0.9%) gave the correct answer for
question number one compared to 25 (22.1%) and 87 (77%) gave
incomplete right and wrong answers respectively. Worse figure
assumed from the second question answers where no valid was
recorded. Results showed 95.6% wrong and 4.4% incomplete right
answers. By answering the third question, 16 dentists (14.2%) feel
comfortable in performing extraction, but 68.75% of them fail to list
correct pre and postoperative precautions compared with 6.25%
incomplete and 25% correct precautions. Among the 97 GDPs who
do not like to do extraction, 34% fail to answer why they do not like
to extract, while 45 dentists (46.4%) refused extraction because of
possible complications but 53.3% of them fail to refer their patients
correctly.
When questionnaire was conducted in different groups, it was
seen that the rate of MRONJ's awareness, self-education and
knowledge were significantly different among all groups with a
lowest rates recorded in GDPs set (Table 4).
4. Discussion
MRONJ is one of prominent complications in the oral and
maxillofacial region due to antiresorptive and antiangiogenic
agents (Ruggiero et al., 2014).
It became a common problem since BPs; which is a group of
antiresorptive drugs; alongwith other antiangiogenic drugs used in
many medical disciplines such as dentistry, orthopedics and
oncology (Fleisch, 2002). They are commonly prescribed for thes.
Sig. DRs-MOH DRs-MHE Sig.
p ¼ 0.188 50% 47.4% P ¼ 0.4
p ¼ 0.044* 28.6% 31.6% P ¼ 0.271
p ¼ 0.372 21.8% 36.8% P ¼ 0.130
eons. DRs: Dental Radiologists. MHE: Ministry of Higher Education, MOH:Ministry of
Table 4
Statistical analysis of MRONJ's awareness, self-education and knowledge rate among groups.
GDPs (Group-1) DRs (Group-2) OMSs (Group-3) ANOVA test Duncan test
A B
Heard about MRONJ before 38/113 (33.6%) 16/33 (48.5%) 27/32 (84.4%) 0.002* 1
2
3
Read about MRONJ 5/38, (13.2%) 10/16 (62.5%) 18/27 (66.7%) 0.001* 1
2
3
Average MRONJ knowledge 16.67% 30.64% 48.55% 0.022* 1
2 2
3
MRONJ: Medication-Related Osteonecrosis of the Jaws. GDPs: General dental practitioners. DRs: Dental radiologists. OMSs: Oral and maxillofacial surgeons.
ANOVA: Analysis of Variance.
*Significant (p < 0.05).
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porosis, Paget's disease, malignant hypercalcaemia, multiple
myeloma, prostate and breast cancer (Conte-Neto et al., 2011;
Arantes et al., 2010; Boissier et al., 2000; Body et al., 1999).
This study surveyed Iraqi GDPs, OMSs, and DRs to assess their
awareness and knowledge towards MRONJ in the form of ques-
tionnaires. Table 5 summarizing the correct answers to
questionnaires.
All respondent were unable to recall any antiangiogenic agent
and only one-surgeon recall medications other than BP as aTable 5
The correct answers to all questionnaires.
Question no. The Correct answer
Oral and Maxillofacial Surgeons
Q1 Many medical conditions like osteopenia, osteoporosis, fibrous dyspla
cancer bony metastasis.
Q2 Antiresorptive drugs like bisphosphonate class (Alendronate, Zolendr
drugs like Denosumab, and Teriparatide.
Q3 If yes, with precautions like a traumatic extraction, antibiotic prophy















Q2 A. MRONJ B. Osteoradionecrosis
Q3 A. Osteosclerosis of the alveolar margin.
B. Thick lamina dura/widening of periodontal ligament.
C. Sequestra.
Q4 Many medical conditions like osteopenia, osteoporosis, fibrous dyapl
cancer, and cancer bony metastasis.
Q5 Antiresorptive drugs like bisphosphonate class (Alendronate, Zolendr
drugs like Denosumab, and Teriparatide.
Q6 B




Q1 Many medical conditions like osteopenia, osteoporosis, fibrous dyapl
breast cancer, and cancer bony metastasis.
Q2 Antiresorptive drugs like bisphosphonate class (Alendronate, Zolendr
drugs like Denosumab, and Teriparatide.
Q3 If yes, with precautions like a traumatic extraction, antibiotic prophy
If no, referral to oro-maxillofacial center.potential cause of osteonecrosis. This may be awing to the fact that
antiangiogenic agents were recently considered as possible cause of
MRONJ (Ruggiero et al., 2014), with few scientific researches dis-
cussed the subject compared to BP.
Results showed that two thirds of GDPs in the present study
were unfamiliar with MRONJ. However, 21.3% of them earned their
academic degree before 2003; where the first case of BRONJ was
reported. Moreover, a large number of GDPs (97, 85.8%) were not
confident in performing extraction for patients receiving anti-
resorptive and/or antiangiogenic medication due to their reducedsia, Paget's disease, multiple myeloma, breast cancer, and
onate, Pamidronate, Risedronate, …), antiangiogenic
laxis, and mouthwash.




asia, Paget's disease, multiple myeloma, breast
onate, Pamidronate, Risedronate, ….), antiangiogenic
ina dura, increased bone density, and sequestration.
asia, Paget's disease, multiple myeloma,
onate, Pamidronate, Risedronate, …), antiangiogenic
laxis, and mouthwash.
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were in the early years of their careers.
Although the initial effect of BPs appear after a few days or
weeks (Li and Davis, 2003; Liberman et al., 1995), MRONJ lesions
may remain silent unless there is a triggering factor such as
chemotherapy drugs, infection or an invasive dental procedure
(Agrillo et al., 2012; Silverman and Landesberg, 2009; Bagan et al.,
2009). However, it may occur suddenly or sometimes the clinical
manifestation of MRONJ presents with negligible superficial signs
and does not always reflect the true extent of the underlying bone
tissue (Cardoso et al., 2017).
DRs should be aware of the radiographic findings, which suggest
the presence of a disease in a specific anatomic region. This can be
achieved by continuous education combined with training in
radiographic interpretation. It is imperative for DRs to be able to
identify ‘at risk’ patients for appropriate advice and management.
In this study, most of DRs who were aware of MRONJ upgraded
their knowledge through continuous education courses or reading
of scientific paper(s) rather than university studies.
When evaluating DRs’ answers, most of DRs listed alveolar
osteitis, retained root, and sharp bone in their differential di-
agnoses. In addition, they suspected to detect sequestra in pano-
ramic radiography only in osteomyelitis. This reflects their low level
of knowledge and awareness about MRONJ despite their
specialization.
The answers of other group questions affected by lack of
adequate knowledge for description of radiographic findings of
MRONJ's early stage, and when to use the appropriate imaging
technique. This can be attributed to the fact that large number of
DRs deal mostly with different dental problems like dental caries,
periodontal disease and periapical lesions, and considered the
more advance cases are of surgeons' specialty.
Majorities of the OMSs in this study, in particular those working
in MOH, were aware of the problem related to anti-resorptive
drugs, and they were better than DRs and GDPs in terms of
MRONJ knowledge and self-learning. Perhaps OMSs are responsible
for treating these cases. Different guidelines of MRONJ manage-
ment makes the strategies of treatment largely based on expert
opinion rather than experimental data (Kyriakidou et al., 2016).
This may explain why no agreement existed among surgeons
regarding different treatment modalities.
Conclusion
Extra focus on MRONJ is essential for dental students in the
dental curriculum, and at the same time strengthen the MRONJ
awareness and knowledge among dentists and patients using the
related medications. However, we suggest that future surveys of
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